510(k) device
VITROS Immunodiagnostic Products hs Troponin I Reagent Pack
Ortho-Clinical Diagnostics, Inc. · Immunoassay Method, Troponin Subunit (MMI, Class II) · First FDA decision Sep 29, 2003, newest Oct 29, 2025Heart attack (myocardial infarction)Heart attack and heart failure blood tests
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
0
Naming "VITROS Immunodiagnostic Products"
MAUDE reports
2,398
Brand "VITROS Immunodiagnostic Products", since 2015
PubMed studies
13
Mentioning "VITROS Immunodiagnostic Products"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing VITROS Immunodiagnostic Products hs Troponin I Reagent Pack
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K252393 · Decided Oct 29, 2025 · 90 days after receipt
Device type: Immunoassay Method, Troponin Subunit (MMI) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "VITROS Immunodiagnostic Products", any status and sponsor, newest update first.
No registered device study names "VITROS Immunodiagnostic Products".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "VITROS Immunodiagnostic Products", and for the whole product code for context.
This brand
2,398 reports: 2,388 malfunction, 10 injury, 0 death
Whole product code MMI
7,546 reports: 7,009 malfunction, 528 injury, 4 death
Newest reports for this brand
Ortho-Clinical Diagnostics, Inc.
3007111389-2026-00163 · Received Oct 16, 2026 · Event dated Sep 17, 2026
Device type: General Purpose Reagent (PPM)
Device problem as coded: Low Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0820-2007 · Started Apr 27, 2007 · Posted by FDA May 26, 2007
Reason given: Quality control and patient results can be lower than expected when the true Troponin I value is less than or equal to 0.2 ng/mL which may result in the device failing to detect myocardial injury.
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Immunoassay Method, Troponin Subunit (MMI)
1 more recall records with a free account
Published research
The most relevant PubMed records for "VITROS Immunodiagnostic Products"[tiab]. The summary above synthesizes these.
- Analytical performance of the VITROS® Immunodiagnostic Products total PSA II and free PSA assays.
De Keukeleire S, Wauters A, Luyts D, et al. · Clin Biochem · 2014Comparative Study, Research Support, Non-U.S. Gov't
- Clinical Performance of an N-Terminal Pro-B-Type Natriuretic Peptide Assay in Acute Heart Failure Diagnosis.
Daniels LB, Ajongwen P, Christenson RH, et al. · J Appl Lab Med · 2025Multicenter Study
- Examination of SARS-CoV-2 serological test results from multiple commercial and laboratory platforms with an in-house serum panel.
Lester SN, Stumpf M, Freeman BD, et al. · Access Microbiol · 2024
- Technical and clinical evaluation of the VITROS® Immunodiagnostic Products 25-OH Vitamin D Total Assay--comparison with marketed automated immunoassays and a liquid chromatography-tandem mass spectrometry method.
Cavalier E, Rousselle O, Ferrante N, et al. · Clin Chem Lab Med · 2013Comparative Study, Research Support, Non-U.S. Gov't
- Clinical evaluation of four commercial immunoassays for the detection of antibodies against established SARS-CoV-2 infection.
Chua KYL, Vogrin S, Bittar I, et al. · Pathology · 2020Comparative Study
- Bimodal distributions of anti-Trypanosoma cruzi antibody levels in blood donors are associated with parasite detection and antibody waning in peripheral blood.
Remesar MC, Sabino EC, Buss LF, et al. · PLoS Negl Trop Dis · 2025Research Support, N.I.H., Extramural
- Declining antibody levels to Trypanosoma cruzi correlate with polymerase chain reaction positivity and electrocardiographic changes in a retrospective cohort of untreated Brazilian blood donors.
Buss LF, Campos de Oliveira-da Silva L, Moreira CHV, et al. · PLoS Negl Trop Dis · 2020Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Is Sunshine Vitamin Related to Adolescent Depression? A Cross-Sectional Study of Vitamin D Status and Depression Among Rural Adolescents.
Tarikere Satyanarayana P, Suryanarayana R, Theophilus Yesupatham S, et al. · Cureus · 2023
- Clinical and Analytical Performance Evaluation of an Automated Procalcitonin Assay.
Ogbonna G, Atienza JR, Singleton DW, et al. · J Appl Lab Med · 2025Evaluation Study
- Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Ammitzbøll C, Bartels LE, Bøgh Andersen J, et al. · ACR Open Rheumatol · 2021
- Clinical Use of a New High-Sensitivity Cardiac Troponin I Assay in Patients with Suspected Myocardial Infarction.
Boeddinghaus J, Twerenbold R, Nestelberger T, et al. · Clin Chem · 2019Multicenter Study, Observational Study
- 0/2ߙh-Algorithm for Rapid Triage of Suspected Myocardial Infarction Using a Novel High-Sensitivity Cardiac Troponin I Assay.
Wildi K, Boeddinghaus J, Nestelberger T, et al. · Clin Chem · 2022
Other devices of this type
Also filed under product code MMI.
- Access hsTnIBeckman Coulter, Inc. · 510(k) 2025
- Elecsys Troponin T Gen 5Roche Diagnostics · 510(k) 2021
- i-STAT hs-TnI cartridge with the i-STAT Alinity SystemAbbott Point of Care, Inc. · 510(k) 2026
- Atellica® IM High-Sensitivity Troponin I (TnIH)Siemens Healthcare Diagnostics, Inc. · 510(k) 2024
- Alinity i STAT High Sensitivity Troponin-IAbbott Laboratories Diagnostics Division · 510(k) 2023
- Vidas Troponin I Ultra (Tniu) Assay, Model 30 448bioMerieux, Inc. · 510(k) 2007
- Dimension Vista Ctni Flex Reagent CartridgeDade Behring, Inc. · 510(k) 2007
- Abbott Axsym Troponin-I AdvAbbott Laboratories · 510(k) 2006
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.